- $2.63m
- $1.39m
Annual balance sheet for TC BioPharm, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 10-K | 10-K |
| Standards: | IFRS | IFRS | IFRS | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.957 | 0.748 | 1.57 | 4.81 | 2.46 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3.02 | 1.24 | 1.48 | 1.78 | 1.1 |
| Prepaid Expenses | |||||
| Total Current Assets | 4.22 | 2.22 | 3.86 | 7.45 | 5.7 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 5.61 | 4.63 | 3.68 | 3.29 | 2.62 |
| Net Intangible Assets | |||||
| Total Assets | 10.1 | 7.27 | 8.02 | 11.3 | 8.93 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.88 | 4.19 | 20.6 | 9.16 | 4.75 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 12.7 | 10.6 | 24.6 | 11 | 6.25 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -2.54 | -3.35 | -16.6 | 0.331 | 2.69 |
| Total Liabilities & Shareholders' Equity | 10.1 | 7.27 | 8.02 | 11.3 | 8.93 |
| Total Common Shares Outstanding |